The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...

A recent clinical trial found that transplantation in lower-risk myelodysplastic syndrome (MDS) patients with high-risk ...

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...

To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...

Patients enrolled had NET liver metastases of any grade or origin that were progressive, symptomatic, or represented a high ...

The US FDA has approved the supplemental new drug application (sNDA) for revumenib (Revuforj) in the treatment of relapsed or ...

Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...

1. Malandrakis, P. Sustained marrow and imaging MRD negativity can lead to lenalidomide discontinuation following ASCT in multiple myeloma: Updated results from a prospective cohort study. Presented ...

El-Khoueiry, MD, an associate professor of clinical medicine in the Division of Medical Oncology and director of the phase I ...

The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...

A panelist discusses how patient comorbidities and declining performance status drive individualized treatment planning in ...

Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and progression-free survival in ...